Chemours Company (The) ($CC) Stock Forecast: Down 5.4% Today

What is Chemours Company (The)?

Chemours (NYSE: CC) is a chemical company recognized for its innovative solutions across industries. Today, the stock witnessed a significant decline in the market.

Why is Chemours Company (The) going down?

CC stock is down 5.4% on Mar 5, 2026 19:56

• Analysts have raised their price targets for Chemours, showing optimism and positive expectations for the stock.
• An investigation into potential claims against Chemours following a stock price decrease due to a one-time inventory charge may have impacted the bearish movement.
• Reports of an executive receiving restricted stock units (RSUs) and shares being held for tax purposes might have also influenced investor sentiment.
• The contrasting information of price target increases and investigations into financial disclosures likely caused uncertainty and contributed to the downward trend in Chemours' market performance today.

CC Price Chart

CC Technical Analysis

CC News

Mizuho Forecasts Strong Price Appreciation for Chemours (NYSE:CC) Stock

Mizuho has increased its price target for Chemours (NYSE:CC) stock from $17.00 to $21.00, reiterating an "outperform" rating and implying a 20.21% upside from the previous closing price. Other firms like Morgan Stanley, Truist Financial, UBS Group, The Goldman Sachs Group, and Jefferies Financial Group have also recently updated their price targets and ratings on Chemours. The stock currently has an average "Hold" rating from analysts with an average target price of $18.40, with institutional investors holding a significant portion of its shares.

https://www.marketbeat.com/instant-alerts/mizuho-forecasts-strong-price-appreciation-for-chemours-nysecc-stock-2026-03-05/

CC: Mizuho Raises Chemours Price Target to $21, Maintains Outper

Mizuho has increased its price target for Chemours (CC) from $17.00 to $21.00, while maintaining an 'Outperform' rating, indicating positive expectations for the stock. This adjustment follows similar actions by other analysts, reflecting varied but generally positive sentiment regarding Chemours' market performance. The average target price from Wall Street analysts is $19.63, suggesting an 11.95% upside from the current price, with GuruFocus estimating a fair value of $21.46.

https://www.gurufocus.com/news/8681486/cc-mizuho-raises-chemours-price-target-to-21-maintains-outperform-rating-cc-stock-news

Bronstein, Gewirtz & Grossman, LLC Is Investigating The Chemours Company (CC) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against The Chemours Company (NYSE:CC) following a significant drop in its stock price. The investigation stems from Chemours's February 19, 2026, disclosure of a negative impact on its 2025 EBITDA due to a one-time inventory charge in its Advanced Performance Materials segment, causing a 16.51% stock decline. Investors who purchased Chemours securities are encouraged to contact the law firm to learn more and assist with the investigation.

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-the-chemours-1140755

Chemours (NYSE: CC) executive gets RSU grant, shares withheld for tax

Chemours executive Gerardo Familiar Calderon reported receiving a grant of 25,708 restricted stock units (RSUs) and had 2,635 shares withheld to cover tax obligations from previously vesting RSUs. The new RSU award will vest in three equal annual installments starting March 1, 2027, and no shares were sold in the tax-withholding transaction, which is exempt under Rule 16b-3. After these transactions, Calderon's holdings total 57,292.1467 shares, including directly owned shares, RSUs, and dividend equivalent units.

https://www.stocktitan.net/sec-filings/CC/form-4-chemours-co-insider-trading-activity-dfacb933bb08.html

Bronstein, Gewirtz & Grossman, LLC Encourages The Chemours Company (CC) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company (NYSE:CC) following a significant stock price drop. The drop occurred after Chemours reported its Q4 and full-year 2025 financial results, which included a one-time inventory charge and stated "short-term cyclical end market headwinds" in its Advanced Performance Materials segment. The firm encourages affected investors to contact them to assist with the investigation, which is conducted on a contingency fee basis.

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-the-chemours-compa-1140754

Trending Today

CleanSpark Inc ($CLSK) Stock Forecast: Down 5.3% Today

FedEx Corporation ($FDX) Stock Forecast: Down 5.0% Today

Teradyne, Inc. ($TER) Stock Forecast: Down 5.2% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.4% Today

J.B. Hunt Transport Services Inc. ($JBHT) Stock Forecast: Down 5.2% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.3% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Up 5.7% Today

Old Dominion Freight Line Inc. ($ODFL) Stock Forecast: Down 5.9% Today

BlackRock Inc. ($BLK) Stock Forecast: Down 6.3% Today

Vornado Realty Trust ($VNO) Stock Forecast: Down 5.1% Today

Chemours Company (The) Price History

20.01.2026 - CC Stock was down 18.3%

• Chemours (CC) encountered a noticeable earnings shortfall in Q4, primarily due to decreasing sales and profitability in its Advanced Performance Materials sector.
• Despite seeing growth in data-center cooling markets, the disappointing earnings report caused a significant drop in Chemours' stock value.
• Although the company made strategic moves to expand in Thermal & Specialized Solutions and Advanced Performance Materials, the lackluster Q4 performance in the APM segment took the spotlight.
• Chemours' failure to meet earnings expectations and the subsequent decline in its stock price underscore the challenges in the APM division, prompting concerns about the company's financial condition and distress signals.

20.01.2026 - CC Stock was down 21.2%

• Chemours (CC) experienced a notable Q4 earnings shortfall, attributed to a decline in sales and profitability within its Advanced Performance Materials segment, resulting in a downturn in the market.
• Despite an uptick in data-center cooling markets, disappointing Q4 performance and earnings contributed to a substantial drop in Chemours' stock value.
• The company's failure to meet estimated Q4 adjusted EPS as per FactSet and the announcement of reduced earnings and sales intensified bearish sentiments.
• Going forward, Chemours projects revenue growth in 2026 driven by Opteon™ Refrigerants demand and cost-saving initiatives, potentially reversing the current downward trajectory of the stock.

20.01.2026 - CC Stock was down 14.3%

• CC reported Q4 earnings that fell short of analyst estimates, with adjusted EPS at $0.05 compared to the expected $0.07, and revenue of $1.3 billion missing the estimated $1.33 billion.
• Despite the earnings miss, the stock experienced significant growth in the last three months, up 84.71%, and 16.76% in the last twelve months, indicating positive investor sentiment prior to the recent earnings report.
• The company attributed the net loss in Q4 and full year to lower cost absorption, non-cash inventory charges, and litigation-related expenses, impacting its financial performance.
• Chemours Co. anticipates future growth in net sales and adjusted EBITDA for 2026, driven by Opteon™ Refrigerants demand and strategic cost reductions, providing a positive outlook despite the current earnings disappointment.

23.01.2026 - CC Stock was up 5.2%

• The stock of Chemours (CC) experienced a strong bullish movement today.
• Positive adjustments to price targets and ratings likely boosted investor confidence in the company's future prospects.
• Despite facing challenges such as disappointing Q4 earnings and ongoing litigation, Chemours' focus on implementing pricing actions and divesting assets to strengthen its financial position seems to have resonated positively with investors.
• The company's projected consolidated net sales growth for 2026 and improved adjusted EBITDA and free cash flow outlook might have contributed to the bullish sentiment surrounding the stock today.

04.02.2026 - CC Stock was up 5.1%

• The upward movement in CC's stock may be attributed to the favorable quarterly EPS results and outperforming expectations despite a decrease in revenue compared to the previous year.
• Actions like equity grants and share withholdings for tax obligations by Chemours executives may have boosted investor confidence in the company's future outlook.
• Following a stock price decline after the financial results, ongoing investigations by a legal firm might have initially caused market uncertainty, but positive performance indicators helped restore investor faith and drive the bullish movement.
• Despite Quantbot Technologies LP reducing its stake in Chemours, the company's dividend announcement and overall financial health likely reassured investors, contributing to the upward trajectory.

03.02.2026 - CC Stock was down 7.9%

• Stake reductions by Quantbot Technologies LP and Vanguard Group Inc. indicate a lack of confidence in the company.
• Negative sentiment is heightened by an ongoing investigation into the company following a stock price drop linked to one-time inventory charges and market challenges.
• Despite surpassing quarterly EPS estimates and achieving a positive return on equity, a year-over-year revenue decline may have contributed to the stock's bearish performance.
• The bullish outlook from FelixQE's Substack, emphasizing the company's undervaluation and growth potential amidst PFAS litigation, stands in contrast to prevailing market sentiment, indicating a divergence in investor perspectives.

24.01.2026 - CC Stock was up 5.0%

• Chemours Co reported a net loss mainly attributed to litigation-related charges and increased costs, impacting its financial performance negatively in its annual Form 10-K report.
• Despite the loss, Chemours is working on strengthening its ties with the semiconductor industry, increasing adoption of its Opteon refrigerants, and streamlining its portfolio through asset sales for debt reduction.
• The company is encountering operational challenges and legal issues, including a lawsuit regarding PFAS contamination. This situation might have influenced the negative market sentiment, although there is anticipated support from its Opteon product line as Jefferies raised its stock price target.

05.02.2026 - CC Stock was down 5.4%

• Analysts have raised their price targets for Chemours, showing optimism and positive expectations for the stock.
• An investigation into potential claims against Chemours following a stock price decrease due to a one-time inventory charge may have impacted the bearish movement.
• Reports of an executive receiving restricted stock units (RSUs) and shares being held for tax purposes might have also influenced investor sentiment.
• The contrasting information of price target increases and investigations into financial disclosures likely caused uncertainty and contributed to the downward trend in Chemours' market performance today.

27.01.2026 - CC Stock was up 5.5%

• Chemours (CC) experienced a bullish trend today due to investor focus on the company's new AI cooling partnership and analyst updates.
• The successful private offering of $700 million in senior notes due 2034 also contributed to the positive market movement.
• Despite concerns raised by a law firm regarding potential securities fraud and market headwinds, the company's undervaluation according to discounted cash flow models and price-to-sales ratios has helped reassure investors.
• The company's valuation and recent financial results have inspired volatility, but the overall market sentiment remains optimistic about Chemours' future prospects.

06.01.2026 - CC Stock was up 5.5%

• Chemours (CC) stock saw a bullish trend today, possibly driven by the anticipation surrounding its upcoming fourth-quarter 2025 earnings release and conference call.
• The market may be reacting positively to the potential for long-term prospects, especially in the titanium dioxide (TiO2) business, despite analysts' expectations of a decline in EPS and revenue for the quarter.
• The announcement of a sustainable 2% yield for Chemours could have also contributed to investor interest in the stock, emphasizing the importance of dividends for total stock market returns.
• Overall, the bullish movement in CC's stock today could be a reflection of investor optimism towards the company's future performance and strategic initiatives, despite near-term challenges.

26.01.2026 - CC Stock was down 5.4%

• The bearish movement in Chemours (CC) stock today could be attributed to profit-taking by investors after a period of undervaluation.
• The increase in price targets by financial institutions may have initially boosted confidence in the stock, but the market sentiment might have shifted due to concerns about the company's negative net margin and P/E ratio.
• The joint development agreement with 2CRSi for advanced cooling solutions could be a positive long-term catalyst for Chemours, but short-term market dynamics might have overshadowed this news.
• Overall, the bearish movement in CC's stock today seems to reflect a mix of valuation concerns, profit-taking, and short-term market sentiment, despite promising developments in its technology partnerships.

10.01.2026 - CC Stock was up 5.2%

• The stock hit a 52-week high due to strong investor confidence and significant gains over the past six months, despite operating with substantial debt.
• Analysts predict profitability this year, with an EPS of $0.91, reflecting positive sentiment towards the company's financial performance.
• The increased stake by the New York State Common Retirement Fund by over 1,000% in Q3 also contributed to the bullish movement, indicating growing institutional interest in Chemours.
• The announcement of the upcoming fourth-quarter earnings release and conference call may have further boosted investor optimism, providing a catalyst for the stock's upward momentum.